Suppr超能文献

嗜麦芽窄食单胞菌的感染与定植:匈牙利一家三级护理中心分离菌株的抗菌药物敏感性及临床背景

Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary.

作者信息

Juhász Emese, Krizsán Gergely, Lengyel György, Grósz Gábor, Pongrácz Júlia, Kristóf Katalin

机构信息

Diagnostic Laboratory of Clinical Microbiology, Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary.

Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary.

出版信息

Ann Clin Microbiol Antimicrob. 2014 Dec 31;13:333. doi: 10.1186/s12941-014-0058-9.

Abstract

BACKGROUND

Stenotrophomonas maltophilia is an important opportunistic, mainly nosocomial pathogen that emerged in the last decades worldwide. Due to its inherent extended antibiotic resistance, therapeutic options are strongly limited. New resistance mechanisms in S. maltophilia make antibiotic therapy even more difficult. The aim of our study was to investigate the antimicrobial resistance of S. maltophilia isolates collected in our laboratory and to reveal related clinical background.

METHOD

Consecutive non-duplicate S. maltophilia isolates (n = 160) were collected in a three-year period. Conventional methods, automated identification system and MALDI-TOF MS was used for identification, ERIC-PCR for genetic relationship analysis and broth microdilution method to determine the susceptibility for trimethoprim/sulfamethoxazole (SXT), ciprofloxacin, levofloxacin, moxifloxacin, colistin, doxycycline and tigecycline. Clinical final reports were used retrospectively to collect clinical information.

RESULTS

ERIC-PCR revealed large heterogeneity. Trimethoprim/sulfamethoxazole, moxifloxacin and levofloxacin were found to be the most effective agents with MIC50/MIC90 0.5/1, 0.25/1, 1/2 mg/l, respectively. Seventy percent of patients with S. maltophilia infection were treated in intensive care units. All-cause mortality rate was 45%. Nearly 70% of the isolates were collected from polymicrobial infections/colonizations.

CONCLUSIONS

Trimethoprim/sulfamethoxazole is the most potent antibiotic agent against S. maltophilia. In case of SXT hypersensitivity, intolerance or resistance, fluoroquinolones are alternative therapeutic options. Missing clinical breakpoints, consensus antibiotic susceptibility testing guidelines and clinical trials make the interpretation of antibiotic susceptibility testing results difficult. The indirect pathogenicity of S. maltophilia in polymicrobial infections or colonizations has to be taken into consideration.

摘要

背景

嗜麦芽窄食单胞菌是一种重要的机会致病菌,主要为医院内病原菌,在过去几十年中在全球范围内出现。由于其固有的广泛抗生素耐药性,治疗选择受到极大限制。嗜麦芽窄食单胞菌新的耐药机制使抗生素治疗更加困难。我们研究的目的是调查在我们实验室收集的嗜麦芽窄食单胞菌分离株的抗菌耐药性,并揭示相关的临床背景。

方法

在三年期间收集连续的非重复嗜麦芽窄食单胞菌分离株(n = 160)。使用传统方法、自动化鉴定系统和基质辅助激光解吸电离飞行时间质谱进行鉴定,采用ERIC-PCR进行遗传关系分析,并使用肉汤微量稀释法测定对甲氧苄啶/磺胺甲恶唑(SXT)、环丙沙星、左氧氟沙星、莫西沙星、黏菌素、多西环素和替加环素的敏感性。回顾性使用临床最终报告收集临床信息。

结果

ERIC-PCR显示出很大的异质性。发现甲氧苄啶/磺胺甲恶唑、莫西沙星和左氧氟沙星是最有效的药物,MIC50/MIC90分别为0.5/1、0.25/1、1/2 mg/l。70%的嗜麦芽窄食单胞菌感染患者在重症监护病房接受治疗。全因死亡率为45%。近70%的分离株来自多微生物感染/定植。

结论

甲氧苄啶/磺胺甲恶唑是针对嗜麦芽窄食单胞菌最有效的抗生素。如果对SXT过敏、不耐受或耐药,氟喹诺酮类是替代治疗选择。缺乏临床断点、共识性抗生素敏感性试验指南和临床试验使得抗生素敏感性试验结果难以解释。必须考虑嗜麦芽窄食单胞菌在多微生物感染或定植中的间接致病性。

相似文献

3
Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates.
Scand J Infect Dis. 2013 Apr;45(4):265-70. doi: 10.3109/00365548.2012.732240. Epub 2012 Oct 31.
4
A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.
J Microbiol Immunol Infect. 2012 Apr;45(2):120-6. doi: 10.1016/j.jmii.2011.09.028. Epub 2011 Dec 11.
6
Levofloxacin-resistant Stenotrophomonas maltophilia: risk factors and antibiotic susceptibility patterns in hospitalized patients.
J Hosp Infect. 2020 Jan;104(1):46-52. doi: 10.1016/j.jhin.2019.09.001. Epub 2019 Sep 7.

引用本文的文献

1
Clonal spread of trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia isolates in a tertiary hospital.
GMS Hyg Infect Control. 2024 May 17;19:Doc26. doi: 10.3205/dgkh000481. eCollection 2024.
4
Bacteremia: From Diagnosis to Treatment.
Infect Dis Clin Microbiol. 2022 Dec 21;4(4):258-267. doi: 10.36519/idcm.2022.187. eCollection 2022 Dec.
6
Correlation between Stenotrophomonas maltophilia incidence and systemic antibiotic use: A 10-year retrospective, observational study in Hungary.
Eur J Microbiol Immunol (Bp). 2024 Mar 5;14(2):185-194. doi: 10.1556/1886.2024.00022. Print 2024 May 14.
8
Clonal dissemination and resistance genes among in a Greek University Hospital during a four-year period.
AIMS Microbiol. 2022 Jul 12;8(3):292-299. doi: 10.3934/microbiol.2022021. eCollection 2022.
9
Risk Factors and Clinical Outcomes of Infections: Scenario in a Tertiary Care Center from South India.
Indian J Crit Care Med. 2022 Aug;26(8):935-937. doi: 10.5005/jp-journals-10071-24288.
10
Emergent Pneumonia in Children.
Front Pediatr. 2021 Jun 17;9:676296. doi: 10.3389/fped.2021.676296. eCollection 2021.

本文引用的文献

1
Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis.
Lancet. 2014 Aug 23;384(9944):703-13. doi: 10.1016/S0140-6736(14)61137-5.
2
Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia.
Eur J Clin Microbiol Infect Dis. 2014 Sep;33(9):1565-72. doi: 10.1007/s10096-014-2101-3. Epub 2014 Apr 30.
3
New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen.
Expert Rev Anti Infect Ther. 2014 Jan;12(1):1-4. doi: 10.1586/14787210.2014.864553. Epub 2013 Dec 4.
4
Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.
Antimicrob Agents Chemother. 2014;58(1):176-82. doi: 10.1128/AAC.01324-13. Epub 2013 Oct 21.
5
Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?
Antimicrob Agents Chemother. 2014;58(1):581-3. doi: 10.1128/AAC.01682-13. Epub 2013 Oct 14.
6
Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.
Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1461-4. doi: 10.1007/s10096-013-1898-5. Epub 2013 May 30.
7
Distinct groups and antimicrobial resistance of clinical Stenotrophomonas maltophilia complex isolates from Korea.
J Med Microbiol. 2013 May;62(Pt 5):748-753. doi: 10.1099/jmm.0.053355-0. Epub 2013 Feb 21.
9
Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.
Antimicrob Agents Chemother. 2013 Mar;57(3):1546-8. doi: 10.1128/AAC.02215-12. Epub 2013 Jan 7.
10
Emergence of VIM-4- and SHV-12-producing Enterobacter cloacae in a neonatal intensive care unit.
Int J Med Microbiol. 2012 Nov;302(6):257-60. doi: 10.1016/j.ijmm.2012.05.003. Epub 2012 Jun 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验